CONTEXT: Because precocious pubarche (PP) reveals late-onset congenital adrenal hyperplasia (LO-CAH) in 5 to 20% of cases, an adrenal stimulation test is recommended in all patients presenting with it. This test is stressful and expensive, and results are normal in more than 80% of cases. OBJECTIVE: Our objective was to identify clinical and plasma predictors of LO-CAH among patients presenting with PP. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective cohort study that included all patients seen for PP at our hospital between 1999 and 2006 (n = 238). All had undergone an ACTH test. MAIN OUTCOME MEASURE: LO-CAH was defined by a post-ACTH 17-hydroxyprogesterone (17-OHP) plasma level greater than 10 ng/ml and confirmed by mutational analysis of the CYP21 gene. The association of standard clinical and laboratory indicators with LO-CAH was assessed. RESULTS: Ten (4%) of 238 patients had LO-CAH. Basal 17-OHP, Delta4-androstenedione, and testosterone plasma levels were significantly higher in these patients. A 2-ng/ml threshold for basal 17-OHP plasma levels offered 100% (95% CI, 69-100) sensitivity for the diagnosis of LO-CAH and 99% (95% CI, 96-100) specificity. CONCLUSION: We identified three plasma predictors of LO-CAH in patients presenting with PP. A selective strategy based on a 2-ng/ml basal 17-OHP plasma level threshold would have safely avoided 99% of the unnecessary ACTH tests among our patients.
CONTEXT: Because precocious pubarche (PP) reveals late-onset congenital adrenal hyperplasia (LO-CAH) in 5 to 20% of cases, an adrenal stimulation test is recommended in all patients presenting with it. This test is stressful and expensive, and results are normal in more than 80% of cases. OBJECTIVE: Our objective was to identify clinical and plasma predictors of LO-CAH among patients presenting with PP. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective cohort study that included all patients seen for PP at our hospital between 1999 and 2006 (n = 238). All had undergone an ACTH test. MAIN OUTCOME MEASURE: LO-CAH was defined by a post-ACTH 17-hydroxyprogesterone (17-OHP) plasma level greater than 10 ng/ml and confirmed by mutational analysis of the CYP21 gene. The association of standard clinical and laboratory indicators with LO-CAH was assessed. RESULTS: Ten (4%) of 238 patients had LO-CAH. Basal 17-OHP, Delta4-androstenedione, and testosterone plasma levels were significantly higher in these patients. A 2-ng/ml threshold for basal 17-OHP plasma levels offered 100% (95% CI, 69-100) sensitivity for the diagnosis of LO-CAH and 99% (95% CI, 96-100) specificity. CONCLUSION: We identified three plasma predictors of LO-CAH in patients presenting with PP. A selective strategy based on a 2-ng/ml basal 17-OHP plasma level threshold would have safely avoided 99% of the unnecessary ACTH tests among our patients.
Authors: Gabriela P Finkielstain; Wuyan Chen; Sneha P Mehta; Frank K Fujimura; Reem M Hanna; Carol Van Ryzin; Nazli B McDonnell; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2010-10-06 Impact factor: 5.958
Authors: Radha Nandagopal; Ninet Sinaii; Nilo A Avila; Carol Van Ryzin; Wuyan Chen; Gabriela P Finkielstain; Sneha P Mehta; Nazli B McDonnell; Deborah P Merke Journal: Eur J Endocrinol Date: 2011-03-28 Impact factor: 6.664
Authors: Aviva B Sopher; Adrienne T Gerken; William S Blaner; Jeremy M Root; Donald J McMahon; Sharon E Oberfield Journal: Fertil Steril Date: 2012-02-17 Impact factor: 7.329
Authors: Aviva B Sopher; Amy M Jean; Sarah K Zwany; Diana M Winston; Christy B Pomeranz; Jennifer J Bell; Donald J McMahon; Abeer Hassoun; Ilene Fennoy; Sharon E Oberfield Journal: Obesity (Silver Spring) Date: 2011-02-10 Impact factor: 5.002
Authors: Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White Journal: J Clin Endocrinol Metab Date: 2010-09 Impact factor: 5.958
Authors: P Cavarzere; M Vincenzi; F Teofoli; R Gaudino; S Lauriola; E Maines; M Camilot; F Antoniazzi Journal: J Endocrinol Invest Date: 2013-09-27 Impact factor: 4.256